Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) EBIT Margin (2022 - 2025)

Historic EBIT Margin for HCW Biologics (HCWB) over the last 4 years, with Q3 2025 value amounting to 21095.26%.

  • HCW Biologics' EBIT Margin fell 202312000.0% to 21095.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 2817.99%, marking a year-over-year decrease of 17572800.0%. This contributed to the annual value of 1148.5% for FY2024, which is 2435400.0% down from last year.
  • As of Q3 2025, HCW Biologics' EBIT Margin stood at 21095.26%, which was down 202312000.0% from 52886.67% recorded in Q2 2025.
  • HCW Biologics' 5-year EBIT Margin high stood at 60.33% for Q1 2022, and its period low was 52886.67% during Q2 2025.
  • Over the past 4 years, HCW Biologics' median EBIT Margin value was 803.09% (recorded in 2024), while the average stood at 8932.1%.
  • As far as peak fluctuations go, HCW Biologics' EBIT Margin skyrocketed by 121338200bps in 2024, and later plummeted by -504408600bps in 2025.
  • Quarter analysis of 4 years shows HCW Biologics' EBIT Margin stood at 422.45% in 2022, then crashed by -93bps to 813.31% in 2023, then rose by 1bps to 803.09% in 2024, then tumbled by -2527bps to 21095.26% in 2025.
  • Its EBIT Margin was 21095.26% in Q3 2025, compared to 52886.67% in Q2 2025 and 38811.49% in Q1 2025.